Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Bart ECG De Goeij, PhD, Maarten L Janmaat, PhD, Grietje Andringa, Laurens Kil, Berris Van Kessel, Kristine A. Frerichs, MD, Andreas Lingnau, Andreas Freidig, Tuna Mutis, MD PhD, A. Kate Sasser, Esther C. W. Breij, Niels W. C. J. Van De Donk, MD PhD, Tahamtan Ahmadi, David Satijn

Blood (2019) 134 (Supplement_1): 3106.

https://doi.org/10.1182/blood-2019-125788

Published: 2019

Journal Articles

Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis

Mitsuhito Hirano, MD, Yoichi Imai, MD PhD, Weng-Chit Ung, MSc, Kota Sato, MD PhD, Muneyoshi Futami, MD PhD, Arinobu Tojo, MD PhD

Blood (2018) 132 (Supplement 1): 4435.

https://doi.org/10.1182/blood-2018-99-110709

Published: 2018

Journal Articles

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Simone C. Oostindie, MSc, Hilma J. Van Der Horst, MSc, Marije B. Overdijk, PhD, Kristin Strumane, PhD, Sandra Verploegen, PhD, Margaret A. Lindorfer, PhD, Erica M. Cook, B.A., Martine E.D. Chamuleau, MD, Tuna Mutis, PhD, Janine Schuurman, PhD, A. Kate Sasser, PhD, Ronald P. Taylor, PhD, Paul W. H. I. Parren, PhD, Frank J. Beurskens, PhD, Esther C. W. Breij, PhD

Blood (2018) 132 (Supplement 1): 4170.

https://doi.org/10.1182/blood-2018-99-114723

Published: 2018

Journal Articles

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Hilma J. Van Der Horst, MSc, Simone C. Oostindie, MSc, Saskia AGM Cillessen, MSc, Anne T Gelderloos, MSc, Marije B Overdijk, Martine E.D. Chamuleau, MD, Esther C. W. Breij, PhD, Tuna Mutis, PhD

Blood (2018) 132 (Supplement 1): 4179.

https://doi.org/10.1182/blood-2018-99-115886

Published: 2018

Journal Articles

Novel ROR1 Antibody Is Able to Trigger Specific and Superior Complement-Dependent Cytotoxicity (CDC) on Primary CLL Cells

Solange R Paredes-Moscosso, Marco Della Peruta, PhD, Satyen Harish Gohil, MBBS MRCP FRCPath, Micaela Harrasser, Amit C Nathwani, MD PhD

Blood (2016) 128 (22): 2052.

https://doi.org/10.1182/blood.V128.22.2052.2052

Published: 2016

Journal Articles

Preclinical Evaluation of CSL362/JNJ-56022473 Single Agent in in Vitro Assays

Khaja Syed, M.S., Christine Pietsch, PhD, Amy Axel, Ann Forslund, PhD, Kate Sasser, PhD, Mark Salvati, PhD

Blood (2015) 126 (23): 4946.

https://doi.org/10.1182/blood.V126.23.4946.4946

Published: 2015

Journal Articles

Effectivity Of Complement-Dependent Cytotoxicity Induced By Therapeutic Antibodies In Acute Lymphoblastic Leukemia Is Dictated By Antigen Expression Levels and Curtailed By Membrane-Bound Complement Regulatory Proteins

Floris C Loeff, MSc, Esther H.M. van Egmond, Judith Olde Wolbers, J.H. Frederik Falkenburg, MD, PhD, Constantijn J.M. Halkes, MD, PhD, Inge Jedema, PhD

Blood (2013) 122 (21): 3909.

https://doi.org/10.1182/blood.V122.21.3909.3909

Published: 2013

Journal Articles

Cord Blood Allograft Rejection Mediated By Coordinated Donor-Specific Cellular and Humoral Immune Processes

Ryo Hanajiri, MD, Makoto Murata, MD, PhD, Kyoko Sugimoto, MD, PhD, Miho Murase, Haruhiko Ohashi, MD, PhD, Tatsunori Goto, MD, Keisuke Watanabe, MD, Nobuhiko Imahashi, MD, Seitaro Terakura, MD, PhD, Tetsuya Nishida, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2013) 122 (21): 4459.

https://doi.org/10.1182/blood.V122.21.4459.4459

Published: 2013

Journal Articles

Enhanced IgG Hexamerization Mediates Efficient C1q Docking and Complement-Dependent Cytotoxicity; Preclinical Proof Of Concept On Primary CLL and Burkitt Lymphoma

Frank J Beurskens, PhD, Rob N de Jong, PhD, Sandra Verploegen, PhD, Marleen Voorhorst, Kristin Strumane, PhD, Margaret A. Lindorfer, PhD, Ronald P. Taylor, PhD, Erica Ollmann Saphire, PhD, Dennis Burton, PhD, Janine Schuurman, PhD, Paul W.H.I. Parren, PhD

Blood (2013) 122 (21): 375.

https://doi.org/10.1182/blood.V122.21.375.375

Published: 2013

Journal Articles

Prenyl Transferases Are Involved in the Regulation of CD20 Levels and Influence Anti-CD20 Monoclonal Antibody-Mediated Activation of Complement-Dependent Cytotoxicity,

Dominika Nowis, MD, PhD, Magdalena Winiarska, PhD, Jacek Bil, MD, PhD, Angelika Muchowicz, MSc, Malgorzata Wanczyk, MSc, Eliza Glodkowska-Mrowka, MD, Kamil Bojarczuk, BSc, Malgorzata Firczuk, PhD, Ewa Wilczek, PhD, Malgorzata Wachowska, MSc, Justyna Chlebowska, MSc, Michal Dwojak, Marta Miaczynska, PhD, Tomasz Stoklosa, MD, PhD, Jakub Golab, MD, PhD

Blood (2011) 118 (21): 3722.

https://doi.org/10.1182/blood.V118.21.3722.3722

Published: 2011

Journal Articles

Anti-CD20-Interferon-α Fusion Protein Demonstrates Potent Direct Growth Inhibition, Antibody-Dependent Cellular Cytotoxicity, and Enhanced Complement-Dependent Cytotoxicity Against Human B Cell Lymphomas In Vitro, and Activity Against Multiple Human NHL Xenografts In Vivo

Reiko E Yamada, Kristopher K Steward, Gataree Ngarmchamnanrith, Sanjay Khare, Raj Sachdev, Iqbal Grewal, Sherie Morrison, John M Timmerman

Blood (2011) 118 (21): 2724.

https://doi.org/10.1182/blood.V118.21.2724.2724

Published: 2011

Journal Articles

Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab

Nisar A. Baig, Ronald P. Taylor, PhD, Margaret A. Lindorfer, PhD, Amy K Church, Betsy R. LaPlant, Emily S. Pavey, Tait D. Shanafelt, MD, Timothy G. Call, MD, Neil Kay, MD, Grzegorz S. Nowakowski, MD, Clive S. Zent, MD

Blood (2011) 118 (21): 2836.

https://doi.org/10.1182/blood.V118.21.2836.2836

Published: 2011

Journal Articles

Complement Activation and Cytotoxicity In CLL Cells Treated with Alemtuzumab and Ofatumumab: Evidence for Multiple Mechanisms of Resistance to Complement Dependent Cytotoxicity

Nisar A Baig, Amy K Church, Grzegorz S. Nowakowski, MD, Ronald P Taylor, PhD, Margaret A Lindorfer, PhD, Clive S. Zent, MD

Blood (2010) 116 (21): 3575.

https://doi.org/10.1182/blood.V116.21.3575.3575

Published: 2010

Journal Articles

CLL Cells From Subjects Treated with Rituximab and Alemtuzumab Can Lose Target Antigen and Develop Resistance to Mab-Mediated Complement Dependent Cytotoxicity

Ronald P Taylor, PhD, Clive S. Zent, MD, Paul V Beum, PhD, Margaret A Lindorfer, PhD, George Weiner, MD

Blood (2010) 116 (21): 3585.

https://doi.org/10.1182/blood.V116.21.3585.3585

Published: 2010

Journal Articles

Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity

Jacek Bil, Magdalena Winiarska, Dominika Nowis, Kamil Bojarczuk, Anna Dąbrowska-Iwanicka, Grzegorz W. Basak, Kazimierz Sułek, Marek Jakobisiak, Jakub Golab

Blood (2010) 115 (18): 3745–3755.

https://doi.org/10.1182/blood-2009-09-244129

Published: 2010

Includes: Supplemental data

Journal Articles

Leukemic CD52 Negative Subclones Due to Defective Glycophosphatidyl-Innositol Anchoring Are Common in Acute Precursor B Lymphoblastic Leukemia, Escape Alemtuzumab Therapy, but Display Increased Sensitivity to Rituximab Mediated Complement Dependent Cytotoxicity: a Mechanistic Rationale for Antibody Combination Therapy.

Bart Nijmeijer, PhD, Marianke LJ Van Schie, Henriette maria Goselink, Roelof Willemze, MD, PhD, J.H. Frederik Falkenburg, MD, PhD

Blood (2009) 114 (22): 835.

https://doi.org/10.1182/blood.V114.22.835.835

Published: 2009

Journal Articles

Treatment Model of CNS Lymphoma Using Complement-Dependent Cytotoxicity Induced by Rituximab and Autoserum.

Yasuyuki Miyake, Yasushi Okoshi, Takayuki Machino, Shigeru Chiba

Blood (2009) 114 (22): 3739.

https://doi.org/10.1182/blood.V114.22.3739.3739

Published: 2009

Journal Articles

Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

Ronald P. Taylor, PhD, Andrew W. Pawluczkowycz, MS, Margaret A. Lindorfer, PhD, Jan G. J. van de Winkel, PhD, Frank J. Beurskens, PhD, Paul W. H. I. Parren, PhD

Blood (2008) 112 (11): 1578.

https://doi.org/10.1182/blood.V112.11.1578.1578

Published: 2008

Journal Articles

IREM-1 Is a Cell Surface Receptor Expressed in AML Blasts: Potential for Targeted Immunotherapy in AML.

Xiaoxian Zhao, PhD, Wouter Korver, Ph.D., Shweta Singh, Eric D. Hsi, M.D., Arie Abo, Ph.D.

Blood (2007) 110 (11): 1792.

https://doi.org/10.1182/blood.V110.11.1792.1792

Published: 2007

Journal Articles

CLL-1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia.

Wouter Korver, Xiaoxian Zhao, Shweta Singh, Eric D. Hsi, Arie Abo

Blood (2007) 110 (11): 2839.

https://doi.org/10.1182/blood.V110.11.2839.2839

Published: 2007

NARROW

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis

Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

Novel ROR1 Antibody Is Able to Trigger Specific and Superior Complement-Dependent Cytotoxicity (CDC) on Primary CLL Cells

Preclinical Evaluation of CSL362/JNJ-56022473 Single Agent in in Vitro Assays

Effectivity Of Complement-Dependent Cytotoxicity Induced By Therapeutic Antibodies In Acute Lymphoblastic Leukemia Is Dictated By Antigen Expression Levels and Curtailed By Membrane-Bound Complement Regulatory Proteins

Cord Blood Allograft Rejection Mediated By Coordinated Donor-Specific Cellular and Humoral Immune Processes

Enhanced IgG Hexamerization Mediates Efficient C1q Docking and Complement-Dependent Cytotoxicity; Preclinical Proof Of Concept On Primary CLL and Burkitt Lymphoma

Prenyl Transferases Are Involved in the Regulation of CD20 Levels and Influence Anti-CD20 Monoclonal Antibody-Mediated Activation of Complement-Dependent Cytotoxicity,

Anti-CD20-Interferon-α Fusion Protein Demonstrates Potent Direct Growth Inhibition, Antibody-Dependent Cellular Cytotoxicity, and Enhanced Complement-Dependent Cytotoxicity Against Human B Cell Lymphomas In Vitro, and Activity Against Multiple Human NHL Xenografts In Vivo

Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab

Complement Activation and Cytotoxicity In CLL Cells Treated with Alemtuzumab and Ofatumumab: Evidence for Multiple Mechanisms of Resistance to Complement Dependent Cytotoxicity

CLL Cells From Subjects Treated with Rituximab and Alemtuzumab Can Lose Target Antigen and Develop Resistance to Mab-Mediated Complement Dependent Cytotoxicity

Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity

Treatment Model of CNS Lymphoma Using Complement-Dependent Cytotoxicity Induced by Rituximab and Autoserum.

Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

IREM-1 Is a Cell Surface Receptor Expressed in AML Blasts: Potential for Targeted Immunotherapy in AML.

CLL-1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only